What is AmideBio?
AmideBio specializes in the development of novel peptide drug candidates aimed at addressing metabolic diseases through its in-silico design and peptide synthesis capabilities. The company also offers custom synthesis services and maintains a catalog of high-purity peptides for clients seeking cost-effective solutions. Their focus is on tackling significant therapeutic challenges in the metabolic disease sector. AmideBio serves a diverse range of clients in the pharmaceutical and biotechnology industries, positioning itself as a key player in the peptide therapeutics market.
How much funding has AmideBio raised?
AmideBio has raised a total of $3.5M across 2 funding rounds:
Private Equity
$763K
Grant
$2.7M
Private Equity (2017): $763K, investors not publicly disclosed
Grant (2022): $2.7M led by The National Institute of Diabetes and Digestive and Kidney Diseases
Key Investors in AmideBio
The National Institute of Diabetes and Digestive and Kidney Diseases
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is a key governmental research body focused on metabolic and digestive health, indicating a strategic alignment with AmideBio's therapeutic focus.
What's next for AmideBio?
The recent major strategic investment provides AmideBio with substantial capital to advance its pipeline of peptide drug candidates for metabolic diseases. This funding is expected to accelerate research and development, potentially leading to clinical trials and further commercialization efforts. The company's dual approach of proprietary drug development and custom synthesis services positions it for sustained growth and impact within the pharmaceutical and biotechnology sectors.
See full AmideBio company page
